While still in the early stages of development, in vivo CAR-T therapies have generated excitement about their potential as cancer therapies, and updates from a couple of class pioneers at ASCO will ...

The steady stream of M&A deals in pharma this year has continued with the news that GSK has agreed to buy Canada's 35Pharma and its drug candidate for pulmonary hypertension (PH) for $950 million. The ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

The Nobel Prize in Chemistry 2026 has been awarded to two scientists - Henri B Kagan and Kensō Soai – for discoveries on ...

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...

Just months after launching an open-source 'virtual biology' platform, non-profit research organisation Biohub has raised ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...